Alergia e Imunologia
Relato de caso | Síndrome inflamatória multissistêmica similar a doença de Kawasaki associada a infecção por SARS-CoV-2 em adulto.
26 Jul, 2021 | 10:16hRelacionado:
Case report: Multisystem inflammatory syndrome in an adult after SARS-CoV-2 infection.
Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection
Case Reports: 2 Adults with Kawasaki-like Multisystem Inflammatory Syndrome Associated with COVID-19
Opinião | Tocilizumabe no tratamento da COVID-19: quem se beneficia e como? – Os pesquisadores sugerem que inibidores de IL-6 talvez devam ser ministrados somente a pacientes com altos níveis de IL-6.
23 Jul, 2021 | 10:18hTocilizumab in COVID-19 therapy: who benefits, and how? – The Lancet
Relacionado: A living WHO guideline on drugs for covid-19 – interleukin-6 receptor blockers are now recommended for patients with severe or critical covid-19. E M-A: Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 – “The 4% absolute risk reduction in mortality from 25% to 21% with IL-6 inhibition added to glucocorticoids may not translate to patients with a lower baseline mortality risk and likely do not justify the additional expense and risk for toxicities for patients hospitalized with modest oxygen requirements and a stable clinical course (from editorial)”. E RECOVERY trial: In hospitalized COVID-19 patients with hypoxia and systemic inflammation (C-reactive protein ≥75 mg/L), tocilizumab improved survival and other clinical outcomes E Secondary analysis of RCT finds Tocilizumab was beneficial to patients hospitalized with Covid-19 if CRP levels were greater than 15.0 mg/dL, but not if CRP levels were 15.0 mg/dL or less. E M-A: Tocilizumab in COVID-19 – “For hospitalized COVID-19 patients, there is some evidence that tocilizumab use may be associated with a short-term mortality benefit, but further high-quality data are required”.
Estudo mostra que vacinas da AstraZeneca e da Pfizer são eficazes contra a variante Delta, mas são necessárias as duas doses.
22 Jul, 2021 | 13:08hComentários: Study Finds Pfizer And AstraZeneca Vaccines Effective Against The Delta Variant — As Long As You Get Both Doses – Forbes E Pfizer’s COVID-19 vaccine works very well against the Delta variant — but only after 2 doses – Insider
Relacionado: [Preprint] 2 doses of Covid vaccines (Pfizer-BioNTech or Oxford-AstraZeneca) highly effective against hospitalization from Delta variant. E Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. E Should I get my second AstraZeneca dose? Yes, it almost doubles your protection against Delta.
Comentário no Twitter
Public Health England's test-negative case-control study for Delta variant now in NEJM: over 14,000 people with Alpha, over 4,000 with Delta https://t.co/3l1QhKeXBT
Vax effectiveness against testing positive for Delta after 2 doses:
– BNT-Pfizer 88.0% (85-90)
– AZ 67.0% (61-72) pic.twitter.com/9UFy6CLSWw— Hilda Bastian, PhD (@hildabast) July 21, 2021
Anticorpos contra COVID-19 persistem por, pelo menos, 9 meses após a infecção – “98,8% das pessoas infectadas em fevereiro/março mostraram nível detectáveis de anticorpos em novembro.”
22 Jul, 2021 | 13:07hComunicado de imprensa: COVID-19 antibodies persist at least nine months after infection – Imperial College London
Estudo original: SARS-CoV-2 antibody dynamics and transmission from community-wide serological testing in the Italian municipality of Vo’ – Nature Communications
Diretriz sobre o tratamento das alergias alimentares mediadas por IgE.
22 Jul, 2021 | 12:51hUpdate of the S2k guideline on the management of IgE-mediated food allergies – Allergologie Select
Especialistas recomendam doses de vacina contra a Covid para algumas pessoas menores de 18 anos no Reino Unido – “A sugestão é que a vacina da Pfizer seja oferecida a jovens entre 16 e 18 anos que façam parte de grupos prioritários ou que vivam com pessoas cujo sistema imunológico esteja debilitado.”
20 Jul, 2021 | 10:52hComentários: Experts recommend Covid jabs for some under-18s in UK – BBC
Posicionamento científico | Recomendações para o uso da budesonida inalatória na COVID-19.
19 Jul, 2021 | 10:05hRecommendations for use of topical inhalant budesonide in COVID-19 – HNO
Relacionado: RCT: Inhaled budesonide shortens recovery time in non-hospitalized patients with COVID-19 E Phase 2 RCT: Inhaled budesonide shows promise for the treatment of early COVID-19
Estudos elucidam aspectos da “long COVID”.
19 Jul, 2021 | 10:01hStudies elucidate poorly understood long COVID – CIDRAP
Sintomas de longo prazo após infecção por SARS-CoV-2 em crianças e adolescentes – “Este estudo mostra uma baixa prevalência de sintomas compatíveis com ‘long COVID’ em uma coorte de crianças aleatoriamente selecionadas e avaliadas 6 meses após o teste por sorologia.”
16 Jul, 2021 | 09:59hLong-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents – JAMA
Vacinação heteróloga com doses da Oxford–AstraZeneca e da Moderna induz aumento nos níveis de anticorpos neutralizantes em comparação a 2 doses da vacina da Oxford–AstraZeneca.
16 Jul, 2021 | 09:58hHeterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination – New England Journal of Medicine
Relacionado: [Preprint] Mixing Covid jabs has good immune response, study finds – “The Com-Cov trial looked at the efficacy of either two doses of Pfizer, two of AstraZeneca, or one of them followed by the other. All combinations worked well, priming the immune system”. E Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”. E RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.
Comentário no Twitter
Health care workers who had received a dose of ChAdOx1 nCoV-19 were offered either ChAdOx1 nCoV-19 or mRNA-1273 9 to 12 weeks later. Levels of S-specific and RBD-specific IgG increased by a factor of 5 after ChAdOx1 nCoV-19 and by a factor of 115 to 125 after mRNA-1273.
— NEJM (@NEJM) July 14, 2021